Rhizen Pharmaceuticals has begun a first-in-human Phase I study of RP6530, a dual Phosphoinositide-3 kinase (PI3K) delta/gamma inhibitor, for the treatment of patients with advanced hematological malignancies. The study is designed primarily to establish the safety and tolerability of RP6530. Secondary objectives include clinical efficacy assessment and biomarker response to allow dose determination and potential patient stratification in subsequent expansion studies. The study will be conducted...